Fragile X Syndrome – Fmr1 KO Mouse Model
Accelerate the availability of targeted FXS therapies with the well-characterized and translationally relevant in vivo Fmr1 KO model
Fmr1 KO Key Model Characteristics
Fragile X Syndrome (FXS) is the most prevalent inherited cause of mild-to-severe cause of intellectual disability and the most common monogenic cause of autism spectrum disorder (ASD). FXS is caused by mutations in the fragile X mental retardation protein 1 (FMR1) gene, resulting in the deficiency of the FMRP protein that plays a key role in synaptogenesis, as well as synaptic plasticity and architecture. The Fmr1 KO mouse model replicates many phenotypic features of human FXS, and therefore, represents a highly translationally relevant mouse model to study efficacy of novel disease-modifying treatments for FXS.Â
InnoSer is committed to helping industry innovators to accelerate the availability of FXS modifying-treatment to patients through our extensive experience in carrying out efficacy studies in the Fmr1 KO mouse model. Accordingly, InnoSer offers preclinical research services focusing on evaluating therapeutic efficacy in the Fmr1 KO mouse model via multiple validated behavioral readouts.Â
✓ Model is characterized on the C57BL/6J and FVB background.Â
✓ Altered spontaneous behaviours, cognitive impairment, hyperactivity, altered anxiety levels, and decreases in social interactions.
✓ Changes in Event-Related Potentials (ERP) in electrocorticography (ECoG) typically observed in FXS patients are detectable in Fmr1 KO mice.
✓ Phenotypic similarities observed are confirmed by extensive in-house validation via several protocols using automated home-cage systems (PhenoTyper™) and conventional behavioural tests (portion of results published together with Kramvis et al., 2013).
✓ Fmr1 KO mice show key FXS characteristics at young age (starting at 6 weeks of age), allowing efficacy testing of targeted interventions as early as post-natal day 1.
Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. We support our clients in identifying new drugs or applications, characterizing their pharmacological properties, and conducting safety and efficacy testing with state-of-the-art readout capabilities and histopathological analysis.Â
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, and gene therapy (viral vectors – e.g.. AAVs).Â
Your Fragile X Syndrome Research Starts Here.
Access detailed study timelines, essential readouts, and robust validation data for the Fmr1 KO mouse model (on C57BL/6J and FVB backgrounds).
Fmr1 KO Sample Data
Fmr1 KO mice show impaired performance in the discrimination learning that can be detected using CognitionWallâ„¢ discrimination learning task
Using the CognitionWallâ„¢, we developed a one-night automated test to efficiently identify discrimination learning impairments in mice, without time-consuming handling of mice. The CognitionWallâ„¢ is a wall with three entrances in front of a food dispenser. Mice are rewarded with a food reward when they choose to pass through one of the three entrances. The rate at which a mouse gains a relative preference for the rewarded entrance is used as a measure of discrimination learning.
Recent literature indicates that clinical EEG recording in FXS patients shows differences in ERP amplitudes; a phenomenon that we also detect in the Fmr1 KO mouse model of FXS.
Experimental setup for auditory event-related potential (AERP) EEG recording. During an ERP recording session, multiple trials are provided with a 100 msec white noise stimulus (~70 dB), with 4-6 sec inter trial interval. Trials with movement artifacts (deducted from XYZ activity) are excluded, generating a clean average AERP trace for the auditory cortex electrode.Â
Fmr1 KOÂ Readouts
Biological Readouts
EEG analyses and post-mortem analyses:
Â
- Baseline spectral analyses of ECoG dataÂ
- Analysis of Auditory event related potentials in ECoG dataÂ
- Tissue collection & analysisÂ
Our Team’s Featured Publications
- Kramvis, I., Mansvelder, H. D., Loos, M., & Meredith, R. (2013). Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model. Frontiers in behavioral neuroscience, 7, 172. https://doi.org/10.3389/fnbeh.2013.00172
The People Behind Your Research
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Discover Other Relevant Rare Genetic Disease Models
Discover InnoSer’s Latest Research
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. Â The ADPD 2025 Conference is...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships Â
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com